ENTA
Enanta Pharmaceuticals Inc
13.00$
+0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -114.1% | -138.8% | -167.7% | -82.2% | -71.2% | -99.1% | -90.4% | 95.6% | -42.9% | -62.8% | -41.7% | -69.4% | -54.1% | |
| 3.5% | 3.6% | 3.6% | 3.3% | 3.3% | 5.2% | 8.1% | 6.6% | 8.5% | 6.7% | 7.0% | 8.3% | 7.6% | |
| 35.5% | 45.0% | 32.6% | 30.1% | 52.8% | 33.4% | 31.4% | 22.8% | 26.7% | 20.5% | 21.8% | 25.6% | 23.4% | |
| 32.8% | -7.7% | -19.6% | 15.0% | 62.7% | 0.7% | 14.1% | 176.4% | 35.6% | -15.5% | -0.3% | 17.5% | 7.6% | |
| 7.2% | 4.4% | 9.8% | 36.4% | 61.3% | 51.6% | 17.0% | 0.8% | 9.6% | 0.8% | 0.1% | 0.0% | 2.5% | |
| 62.5% | -72.9% | 343.8% | -35.3% | 130.6% | 406.3% | -29.3% | -144.6% | 15.2% | -254.1% | 69.6% | 97.5% | -29.2% | |
| -0.1% | -1.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -49.7% | -29.1% | – | – | – | -31.5% | – | – | – | |
| -0.1% | -40.8% | -37.6% | -37.0% | -49.4% | -29.4% | -46.1% | -35.1% | -55.0% | 344.5% | -42.5% | -38.6% | 65.9% | |
| -51.7% | -252.5% | 138.4% | -154.5% | 10.0% | 277.8% | -165.8% | -84.1% | -82.7% | 27.6% | -14.6% | -10.5% | -17.5% | |
| -121.3% | -143.2% | -177.5% | -118.6% | -132.5% | -150.6% | -107.4% | 94.7% | -52.5% | -63.6% | -41.8% | -69.5% | -56.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.